BNC-210

DB19048InvestigationalSmall molecule

BNC-210 is under investigation in clinical trial NCT04951076 (A Phase 2b Study of BNC210 Tablet Formulation in Adults With Post-traumatic Stress Disorder (PTSD)).

Mechanism: Pharmacologically active on Neuronal acetylcholine receptor subunit alpha-7
Curator reviewed
Formula / weight: C₂₄H₂₆N₄O₃ · 418.497 g/mol (avg)
Also known as: 1,8-NAPHTHYRIDIN-4(1H)-ONE, 6-((2,3-DIHYDRO-1H-INDEN-2-YL)AMINO)-1-ETHYL-3-(4-MORPHOLINYLCARBONYL)- · 6-((2,3-dihydro-1h-inden-2-yl)amino)-1-ethyl-3-(4-morpholinylcarbonyl)-1,8-naphthyridin-4(1h)-one
Code names: BNC-210 · IW-2143

Resolves to

Compound

UNIIQP49AY37OYCAS1020634-41-6

Structure

InChIKeyZAEIHDZLLJCJFP-UHFFFAOYSA-NSMILESCCN1C=C(C(=O)N2CCOCC2)C(=O)C2=CC(NC3CC4=CC=CC=C4C3)=CN=C12

Targets

P36544CHRNA7

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

4Clinical trialsPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with BNC-210, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account